What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis

• Published in: Lipids in health and disease Vol. 16; no. 1; p. 111
• Main Authors: Qiu, Chengfeng, Zeng, Pingyu, Li, Xiaohui, Zhang, Zhen, Pan, Bingjie, Peng, Zhou Y F, Li, Yapei, Ma, Yeshuo, Leng, Yiping, Chen, Ruifang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12.06.2017; BioMed Central; BMC
• Subjects: Alleles; Blood lipids; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - blood; Cardiovascular Diseases - genetics; Cardiovascular Diseases - pathology; Cardiovascular risk; Cholesterol; Cholesterol, LDL - genetics; Genetic Association Studies; Genetic Predisposition to Disease; Health risk assessment; Humans; Lipids; Lipids - blood; Lipids - genetics; Lipoproteins; Low density lipoprotein; Meta-analysis; Mutation; Polymorphism, Single Nucleotide; Polymorphisms; Proprotein Convertase 9 - genetics; Proprotein convertase subtilisin/kexin type 9; Public health; Risk Factors; Serum lipids; Single nucleotide polymorphisms; Triglycerides; Triglycerides - blood; Triglycerides - genetics; Lipids; Proprotein convertase subtilisin/kexin type 9; Polymorphisms; Cardiovascular risk; Meta-analysis

PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-function mutations, respectively. The effects of these polymorphisms on serum lipid levels and cardiovascular risk remain to be elucidated. In this meta-analysis, we explored the association of PCSK9 rs505151 and rs11591...